UK-based Cellular Goods has appointed author Gill Whitty-Collins and marketing executive Misha Sher as NEDs.
The pair have been appointed as NEDs in a shake up of the company’s board. Whitty-Collins succeeds David Gardner, who is leaving due to time commitments at his other business interests, and Sher succeeds Ross Connolly.
NED Darcy Taylor will also assume the role of non-executive chairman, succeeding Peter Wall. Wall is stepping down as chairman in order to devote more time to his existing executive roles and increased commitments but will remain a NED of the Company.
Non-executive chairman of Cellular Goods, Darcy Taylor, commented: “I’m delighted to accept the baton from Peter as Cellular Goods embarks on the next phase of its development. On behalf of the Board, I would like to thank David and Ross for their contributions and wish them all the best in their future endeavours.
“I would also like to welcome Gill and Misha. They have an impressive track record, and their counsel will enhance the Board’s strategic oversight of the Company. The Board looks forward to working closely with the senior executive team under our chief executive, Anna Chokina, to drive the Company’s growth and deliver long term value for shareholders.”
Whitty-Collins joined Cellular Goods as a leader in business, brand-building, equality and diversity with more than 25 years’ senior leadership experience at Procter & Gamble (P&G), where she led global brands such as Olay, Always and Pantene, latterly as Senior Vice President for the beauty care business for Europe, India, Middle East & Africa.
She is also the author of ‘Why Men Win at Work… and how we can make inequality history’ with extensive experience and knowledge of the gender inequality issue and how to address it.
Sher is a senior marketing executive with over two decades of experience working with leading brands, rights holders and talent. Mr Sher spearheaded the growth of an award-winning sports, entertainment and culture business unit at MediaCom, one of the world’s largest media and communications agencies.
He has worked with some of the world’s largest brands including eBay, Uber, Coca-Cola, P&G, American Airlines, Apple and Toyota on investment in leading cultural properties. He currently serves as NED at the European Sponsorship Association.
Former Clinton administration advisor joins cannabis board
FoliuMed has announced a new appointment to its advisory board.
FoliuMed has announced the appointment of former advisor to the Clinton administration Howard Glicken to its advisory board.
Glicken will be Brigit a waltz of experience to the FoliuMed advisory board. Having served as a private sector advisor to the Clinton administration on Latin American affairs, Glicken was also the President´s private sector delegate to the Inaugurations of Presidents of Argentina, Uruguay, Peru and Ecuador.
Additionally, he testified before the US Congress on the Free Trade Area of the Americas and is a member of the US/Brazil Business Development Council.
In his role at FoliuMed, Glicken will expand institutional and business relationships in the Americas.
Glicken commented: “What impresses me most about FoliuMed is its leadership team led by founder Oliver Zugel.
“Since 2018 it has built the company with its own capital and is selling innovative products in eight countries. By sourcing cannabis ingredients from its farm in Colombia, it offers German pharma-quality at affordable prices.”
Oliver Zugel, founder of FoliuMed, a medical cannabis company with manufacturing and R&D in Germany and cultivation in South America, commented: “We are honoured to be able to count on Howard’s advice and mentorship, including his views on the upcoming German adult-use regulations.
“His over 40 years of experience in business and politics and background as a successful entrepreneur make him a valued member of our advisory board.”
During his political career, Glicken also has been national vice chairman of finance of the Democratic Party, a member of the national finance board of directors and a managing trustee of the party.
He also was state finance chair for Al Gore for President 1988, state finance chair for Senator Bob Kerrey for President in 1992, state co-finance chair for President Clinton and a trustee of the Vice President’s Residence Foundation.
Former GSK director joins cannabis company
Bill Purves has joined Brains Bioceutical as chief commercial officer.
Former GlaxoSmithKline executive director, Bill Purves, has joined global manufacturer of naturally-sourced active pharmaceutical ingredients, Brains Bioceutical, as its chief commercial officer.
Bill Purves will now be at the forefront of a new frontier in the research and development of cannabinoids for health and wellness sectors, says Brains Bioceutical.
Purves will be responsible for the company’s global sales and marketing operations, and the company says he will diversify its product offerings while playing a pivotal role in the evolution of cannabinoid science.
“After many years in the pharmaceutical industry, combined with time spent working in the cannabis industry, I have the utmost confidence in what we’re doing at Brains Bioceutical,” commented Purves.
“I’m excited to see the potential of cannabinoid pharmaceuticals come to life and the positive impacts this will have in pharmacological advancements.
“We are looking at the future of disease treatment and prevention here at Brains Bioceutical.”
Ricky Brar, CEO of Brains Bioceutical, commented: “Brains is in a unique position to rapidly capitalise on our industry-leading Cannabinoids API via the pharmaceutical industry, and now with Novel Foods Validation in both the EU and UK, Brains will emerge as the industry leader in nutraceuticals.
“Bill Purves, in his role as chief commercial officer of Brains Bio, is ideally positioned to lead these categories, within an emerging global leader.
“His experience will be an asset as we continue to innovate and lead in the cannabinoid space.”
With experience in the pharmaceutical and phytocannabinoid industries, Purves will lead Brains Bio’s business development strategy, explore new revenue streams and solidify relationships with existing and prospective customers.
Starting his pharmaceutical career with GlaxoSmithKline in 1994 as senior financial analyst, he then moved into the role of chief financial officer of the company’s business operations in Sub-Saharan Africa.
Five years later, Purves was promoted to executive director of GlaxoSmithKline’s international business development, providing strategic planning and market development support across the company’s international business unit.
In 2007, where Purves was responsible for establishing the Iroko Pharmaceuticals’ global sales and distribution networks for branded generic and specialty prescription products. He later co-founded and acted as managing member of Windhoek Healthcare, a US-based healthcare investment firm, which launched three specialty pharmaceutical companies.
Purves entered the medical cannabis space in 2018 when he was hired by Jacana, a Jamaican medical cannabis company, as its CCO and CFO, where he helped transform the startup into a fully, vertically integrated medical cannabis company with business arms that included research and development, cultivation, production and extraction.
Tony Reeves of EIHA: cannabis has been an exciting journey
European Industrial Hemp Association (EIHA) board member Tony Reeves discusses his journey into cannabis.
Fate, serendipity, luck? My hemp journey started through a combination of all three, and of all the journeys I have embarked on throughout my career, this has been by far the most challenging, exciting and satisfying, of that, I am sure!
Back in 2014, I was European MD of a meat-free business, selling a range of vegetarian burgers, mince, balls and so on. We had achieved some nice distribution with listings in the Co-operative supermarket, Holland & Barrett, and a major own-label supply contract with Tesco. Ironically, for a number of reasons, I wasn’t a particular fan of soya (the main ingredient) and started to explore alternative plant proteins.
One morning over breakfast, for some reason my wife said “what about hemp?” Now at the time, like most people, I had of course heard of hemp but (again like many people) I had a limited understanding of its incredible range of applications. This is best defined by the three statements I was to hear many times in the months to come.
“It’s a good fishing bait, isn’t it?” – yes is it! “We used to make rope from it didn’t we?” – yes we did! And perhaps the most common misconception: “Can’t you smoke it (followed often by a knowing wink)” – not if you are looking for the effect that I think you are!
On day one of my research, I found this nice guy in Phoenix who had a patent for the extraction of protein from hemp seed – and this was the launch of my ‘hemp journey’ proper, as he put me in touch with some equally nice people in Vancouver who, it appears, had started the Canadian hemp seed industry some 15 years earlier. This family business was called ‘Hempco’ but later become part of ‘Aurora Cannabis’ and was renamed ‘Aurora Hemp.’ After several conversations and several months, I met with the family and was so impressed by their passion, mission and the opportunities represented by this amazing plant that I joined them with responsibility for the European expansion.
| already had lots of contacts and great relationships across the commercial sector, so getting meetings at a senior level was not a problem. However, I soon discovered that the level of understanding around hemp and its benefits was similar to mine at the start of my journey, i.e. tending towards zero (if you discount the aforementioned cliches!). So, I had now become a ‘hemp educator/evangelist’ not through design but through necessity!
Later, through another stroke of luck, I met another nice guy (lots of these in our industry as I have discovered) called Jacek Kramarz, who introduced me to CBD – now I was aware of it (and suitably impressed by it), but I was so busy lecturing anyone who would listen on the nutritional benefits of hemp seed and its derivatives that I had done little research on this aspect. Next day (not really, but it felt like it!) | was on a plane to Poland and my passion/obsession with CBD began – and has been developing ever since!
Events soon accelerated, I become part of EIHA’s Advisory team, began representing the industry (with Catherine Wilson) to UK regulators including the FSA, the Home Office and notably helped shift the MHRA position away from would have been a de-facto ‘ban’ on CBD supplements back in 2016. At the European level contributed to the production of various papers and was part of the EIHA delegation to Brussels – this was a presentation to the PAFF Committee on the subject of Novel Foods.
Over the last few years, my passion for the plant and my dedication to the industry has only intensified to the point that it feels like a moral duty to contribute – let’s face it, the people, the planet and the economy need it like never before!
In previous lives I was a government scientist, ran my own laboratory business and was marketing director for one of Europe’s leading Food & Drink research associations; one of the many things I love about the hemp industry is that it allows me to combine my scientific and business background to best affect – a perfect marriage!
Currently, I am particularly involved in all things CBD and increasingly the minor cannabinoids such as CBG. I am still closely engaged with the FSA and the Home Office and have built some good relationships with parliamentarians and Whitehall. I am a member of the UKAS-led ‘CBD Food Product Approval Expert Group’ the Food & Drink Federations CBD Working Group’ and consultant with several UK, European and North American organisations including THG (market cap £3.9bn).
So, my hemp journey was never planned, but once started, the road ahead was brightly lit, and I am absolutely sure the most exciting part of the story is yet to be written – and I hope to be one of the co-authors!
- New agreement to fund Phase II trials for cannabis glaucoma treatment
- Discover Europe’s first registered cannabis seedbank
- What can Uruguay teach the UK about cannabis policy?
- Flora Growth steps up international growth strategy with opening of offices in London
- Roundup of Q1 2022 financial results in the UK medical cannabis space